弘则医药：高值耗材反内卷 20250812 我们在欧洲市场上的冠脉通路类产品非常全面，包括造影三件套、导管、导丝、 各种球囊等日常 PCI（经皮冠状动脉介入治疗）所需的所有基本和复杂产品。 这些产品都已获得 CE 认证，并且已经销售多年，销量也逐渐增长。 欧洲冠脉通路类耗材市场格局如何？ 摘要 惠泰在欧洲市场冠脉通路类产品线全面，已获 CE 认证并销售多年，销 量稳步增长，覆盖造影三件套、导管、导丝、球囊等 PCI 所需产品。 欧洲冠脉通路耗材市场主要由美敦力和雅培主导，泰尔茂在鞘、亲水导 丝和球囊方面具有较高知名度，中国企业如汇泰和博迈在特定细分领域 崭露头角。 惠泰通过差异化设计如延伸导管和微导管，打破中国品牌同质化印象， 提升品牌形象，并逐步优化其他产品以扩大市场份额，预计未来增长率 可达 40%-50%。 惠泰在欧洲市场主要通过分销模式销售，每个国家有多个经销商负责不 同区域和领域，随着市场打开，将细化到每个地区一个代理商。 惠泰在欧洲使用 APP Medical 自有品牌，延伸导管销量可排名前四，但 球囊等日常使用设备因竞争激烈，难以进入前五。 欧洲市场通路类产品出厂价与国内集采价大致相当，价格浮动 ...

Core Viewpoint - The report outlines the equity change in Lanfang Medical Co., Ltd. due to Shandong Langhui Petrochemical Co., Ltd. increasing its stake to 52.0395% in Lanfang Investment, resulting in a dilution of Lanfang Group's shareholding from 98% to 47.0013% [1][2][16]. Group 1: Equity Change Details - Shandong Langhui's investment in Lanfang Investment was made through a capital increase, where it converted its debt of RMB 109,096.0961 million into equity [20][21]. - The registered capital of Lanfang Investment increased from RMB 89,600 million to RMB 186,820.4058 million, with RMB 97,220.4058 million allocated to registered capital and RMB 11,875.6903 million to capital reserves [18][19]. - The equity change was executed without any other shareholders exercising their preemptive rights [19]. Group 2: Financial Overview of Shandong Langhui - As of the report date, Shandong Langhui's total assets were RMB 494,725.12 million, with total liabilities of RMB 336,848.50 million, resulting in net assets of RMB 157,876.62 million [10]. - The company's revenue for the year 2024 was RMB 1,341,548.59 million, with a net profit of RMB 21,266.65 million [10]. - The net asset return rate was 13.47%, and the asset-liability ratio stood at 68.09% [10]. Group 3: Business Operations and Independence - Shandong Langhui specializes in the research, production, and sales of fine chemicals, primarily producing plasticizers and PVC resin products [9][12]. - The equity change will not affect Lanfang Medical's independence in operations, assets, personnel, finance, and business [24][25]. - Shandong Langhui has committed to maintaining the independence of Lanfang Medical and avoiding any interference in its operations [24][25]. Group 4: Future Plans and Commitments - Shandong Langhui has no plans to further increase or dispose of its shares in Lanfang Medical within the next 12 months following the equity change [16][22]. - There are no plans for significant adjustments to Lanfang Medical's main business, asset restructuring, or changes in management within the next year [22][23]. - Shandong Langhui has pledged to avoid any competition with Lanfang Medical and its subsidiaries [27][28].

证券研究报告 医药生物 | 医疗器械 非金融|公司点评报告 hyzqdatemark 2025 年 05 月 06 日 证券分析师 刘闯 SAC：S1350524030002 liuchuang@huayuanstock.com 林海霖 SAC：S1350524050002 linhailin@huayuanstock.com 市场表现： | 基本数据 | 年 | 04 | | | 2025 | 月 | | | | | 30 | 日 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 收盘价（元） | | | | 9.70 | | | | | | | | | | | 一 年 内 高 最 | | | | | | | 低 | 最 | / | 13.08/7.27 | | | | | （元） | | | | | | | | | | | | | | | 总市值（百万元） | | | 4,010.52 | | | | | | | | | | | | 流通市值（百万元） | | | | | ...

创业板投资风险提示 本次发行股票拟在创业板上市，创业板公司具有创新投入大、新旧产业 融合存在不确定性、尚处于成长期、经营风险高、业绩不稳定、退市风险高 等特点，投资者面临较大的市场风险。投资者应充分了解创业板的投资风险 及本公司所披露的风险因素，审慎作出投资决定。 国科恒泰（北京）医疗科技股份有限公司 （北京市北京经济技术开发区经海四路 25 号 6 号楼 5 层 501C 室） 首次公开发行股票并在创业板上市 招股说明书 保荐人（主承销商） （深圳市福田区福田街道金田路 2026 号能源大厦南塔楼 10-19 层） 招股说明书 声明 中国证监会、交易所对本次发行所作的任何决定或意见，均不表明其对发 行人注册申请文件及所披露信息的真实性、准确性、完整性作出保证，也不表 明其对发行人的盈利能力、投资价值或者对投资者的收益作出实质性判断或保 证。任何与之相反的声明均属虚假不实陈述。 根据《证券法》规定，股票依法发行后，发行人经营与收益的变化，由发 行人自行负责；投资者自主判断发行人的投资价值，自主作出投资决策，自行 承担股票依法发行后因发行人经营与收益变化或者股票价格变动引致的投资风 险。 1-1-1 招股说明书 ...